ChatGPT Parent Open AI Partners With Sanofi, Formation Bio To Boost AI-Driven Drug Development
ChatGPT Parent Open AI Partners With Sanofi, Formation Bio To Boost AI-Driven Drug Development
Tuesday, French drugmaker Sanofi SA (NASDAQ:SNY) announced its collaboration with OpenAI and Formation Bio to accelerate drug development projects.
週二，法國製藥商賽諾菲公司（納斯達克股票代碼：SNY）宣佈與OpenAI和Formation Bio合作，以加快藥物開發項目。
Also Read: Drugmaker Sanofi's Strong Dupixent And Beyfortus Vaccine Sales Propel Q1 Earnings.
另請閱讀： 製藥商賽諾菲強勁的Dupixent和Beyfortus疫苗銷售推動了第一季度的收益。
Sanofi said the partnership with OpenAI will allow it to access proprietary data to develop AI models for its biopharma models, while Formation Bio will provide additional engineering resources.
賽諾菲表示，與OpenAI的合作將使其能夠訪問專有數據，爲其生物製藥模型開發人工智能模型，而Formation Bio將提供額外的工程資源。
The three teams will combine data, software, and tuned models to develop custom, purpose-built solutions for the drug development lifecycle.
這三個團隊將結合數據、軟件和調整後的模型，爲藥物研發生命週期開發定製的專用解決方案。
OpenAI will contribute access to AI capabilities, including the ability to fine-tune models, deep AI expertise, and dedicated thought partnerships and resources.
OpenAI 將提供獲得人工智能功能的機會，包括微調模型的能力、深厚的人工智能專業知識以及專門的思想夥伴關係和資源。
Formation Bio, an AI and tech-driven drug developer with its pipeline of drug assets, will provide engineering resources, experience operating at the intersection of pharma and AI, and its tech-driven development platform to design, develop, and deploy AI technologies across all aspects of the pharma lifecycle.
Formation Bio是一家擁有藥物資產管道的人工智能和技術驅動的藥物開發商，將提供工程資源、在製藥和人工智能交匯處的運營經驗以及技術驅動的開發平台，用於設計、開發和部署製藥生命週期的各個方面的人工智能技術。
The potential benefits of AI for patients awaiting new treatments are immense, and Sanofi, Formation Bio, and OpenAI aim to set the standard for drug developers.
對於等待新療法的患者來說，人工智能的潛在好處是巨大的，賽諾菲、Formation Bio和OpenAI的目標是爲藥物開發商設定標準。
Last month, Moderna Inc (NASDAQ:MRNA) and Microsoft Corp (NASDAQ:MSFT)-backed OpenAI announced their ongoing collaboration to co-innovate.
上個月，摩德納公司（納斯達克股票代碼：MRNA）和微軟公司（納斯達克股票代碼：MSFT）支持的OpenAI宣佈正在進行合作以共同創新。
Moderna began a collaboration with OpenAI in early 2023 with the launch of Moderna's own instance of ChatGPT, called mChat. The company announced Wednesday that it has reached more than 80% internal adoption of mChat, which has accelerated the AI culture at Moderna.
Moderna 於 2023 年初開始與 OpenAI 合作，推出了 Moderna 自己的名爲 mChat 的 ChatGPT 實例。該公司週三宣佈，其內部對mChat的採用率已達到80％以上，這加速了Moderna的人工智能文化。
Price Action: SNY shares are down 0.62% at $48.12 during the premarket session at last check Tuesday.
價格走勢：週二最後一次盤前交易中，紐約證券交易所股價下跌0.62％，至48.12美元。
Photo via Shutterstock
照片來自 Shutterstock